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PENILAIAN TENTANG PENGETAHUAN DAN NATIJAH 
RAWATAN TUBERKULOSIS DALAM KALANGAN 
POPULASI  AWAM DAN BERPENYAKIT DI TIMUR 
LAUT LIBYA 
ABSTRAK 
Tuberkulosis (TB) masih kekal sebagai penyebab utama kematian dan 
morbiditi dalam kalangan orang dewasa, dengan anggaran 9 juta kes baru 
dikesan di seluruh dunia setiap tahun.  Libya menghadapi peningkatan 
secara perlahan dalam prevalans TB dari tahun 2000 hingga 2006, dan ia 
memerlukan pertimbangan sewajarnya daripada pengamal  penjagaan 
kesihatan untuk mengurus TB secara efektif.  Dalam konteks ini, penilaian 
pengetahuan yang berkaitan TB dalam kalangan populasi umum dan 
berpenyakit adalah perlu dalam usaha merangka program pencegahan dan 
penyembuhan kesihatan awam yang efektif. Di samping itu, penilaian 
natijah rawatan boleh membantu dalam mengenali pasti jurang yang perlu 
ditangani. 
Suatu kajian rentas-silang dijalankan dari 1 Januari 2009 hingga 31 
Disember 2009. Kajian ini dibahagikan kepada dua bahagian. Dalam 
bahagian pertama, satu soal selidik yang mengandungi  32  soalan (yang 
mencakupi sosiodemografi, penyebab, gejala, penularan / penyebaran, 
diagnosis,  faktor risiko, rawatan dan pencegahan TB) diedarkan kepada 
peserta kesihatan (yang bersetuju menyertai kajian) dari lima buah 
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bandaraya di Libya (Benghazi, Almarj, Albayda, Darna and Tobruk). Kedua, 
soal selidik yang sama juga diedarkan kepada pesakit tuberkulosis pumonari 
yang baru berdaftar di Quefia Chest Hospital dan Shahat Chest Hospital di 
Timur Laut Libya. Pada bahagian kedua kajian ini, rekod perubatan bagi 
semua pesakit tuberkulosis pulmonari yang berdaftar di kedua-dua hospital 
tersebut dalam tempoh Januari 2007 hingga 31 Disember 2008 diekstrak 
secara retrospektif untuk menilai natijah rawatan.     
Hasil kajian menunjukkan bahawa min skor pengetahuan dalam 
kalangan populasi awam dan populasi berpenyakit adalah 11.47±3.96, 
10.75±4.3 masing-masing. Kerakyatan, pendidikan, pendapatan dan 
kediaman / residen didapati signifikan dengan skor pengetahuan.  Natijah 
rawatan tuberkulosis dari segi kejayaan dan kegagalannya adalah  58.7% dan 
41.3%, masing-masing. Perkadaran kegagalan yang amat tinggi adalah 
dalam kalangan ‘defaulter’ (n=90), diikuti ‘transferred out’ (n=26) dan mati 
(n=11). Kerakyatan dan pendidikan mempunyai kaitan positif yang 
sederhana dengan kejayaan rawatan. Sementara itu, lelaki, tinggal di 
kawasan luar bandar, dan perokok mempunyai perkaitan yang amat negatif. 
Kerakyatan, jantina, kawasan kediaman, diabetes dan merokok  secara 
signifikan berkaitan dengan kegagalan rawatan, sementara diabetes 
mempunyai perkaitan yang sederhana negatif. Secara am, pengetahuan 
tentang TB dalam kalangan populasi yang sihat dan yang berpenyakit adalah 
tidak mencukupi. Kajian mengenal pasti beberapa jurang dalam kawasan 
penularan, faktor risiko, diagnosis dan pencegahan tuberkulosis. 
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Selanjutnya, jurang tersebut adalah predominan dalam kalangan responden 
bukan rakyat Libya, dtinggal di luar bandar dan yang berpendidikan serta 
berpendapatan rendah.  
Bagi pesakit tuberkulosis pulmonari smer positif, sasaran 85% 
WHO/IUATLD bagi kejayaan natijah tercapai. Penambahbaikan 
infrastruktur klinik dan makmal di kawasan terpencil, mendidik ‘defaulter’ 
tentang manfaat melengkapkan terapi dan menstratakan orang asing sebagai 
kumpulan berisiko tinggi boleh meningkatkan kadar kejayaan rawatan. 
Selanjutnya, program pendidikan khusus hendaklah dibangunkan untuk 
menyebarluaskan pengetahuan tentang tuberkulosis kepada pesakit dan ahli 
masyarakat, terutamanya mereka yang tergolong dalam strata yang margiral. 
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ASSESSMENT OF KNOWLEDGE AND EVALUATION OF 
TUBERCULOSIS TREATMENT OUTCOMES AMONG 
GENERAL AND DISEASED POPULATIONS IN NORTH 
EAST LIBYA 
ABSTRACT 
Tuberculosis (TB) still remains a leading cause of adult mortality and 
morbidity with an estimated 9 million new cases detected around the globe 
annually.  Libya has faced gradual increase in the prevalence of TB from 
2000 to 2006 and this had posed considerable challenges for the healthcare 
providers to manage TB timely and effectively. Within this context, 
assessment of TB related knowledge among general and diseased population 
is necessary in order to plan effective public health curative and preventive 
programs. In addition, evaluation of treatment outcomes can further lead to 
identify gaps that need to be addressed while designing appropriate health 
based interventions. 
  A cross sectional study was conducted from 1st January 2009 to 31st 
December 2009. The study was divided into two sections. For the first 
section, a pre-validated questionnaire covering 32 questions on the socio-
demographics, causes, symptoms, transmission, diagnosis, risk factors, 
treatment and prevention of TB was administered to 1000 consented healthy 
participants from five Libyan cities (Benghazi, Almarj, Albayda, Darna and 
Tobruk). Secondly, the same questionnaire was also administered to newly 
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register pulmonary tuberculosis patients in Quefia and Shahat Chest 
Hospitals in North East of Libya.  In the second part of this study, medical 
records of all pulmonary tuberculosis patients registered in Quefia and 
Shahat Chest Hospitals during January 2007 to December 2008 were 
extracted retrospectively to evaluate treatment outcomes of pulmonary 
tuberculosis patients.  
              The study findings revealed that mean knowledge score among 
general public and diseased population was 11.47±3.8 and 10.75±4.3 
respectively. Nationality, education, income and residency were found 
significant with knowledge scores. Tuberculosis treatment outcomes in 
terms of success and failure were 58.7 % and 41.3%, respectively. Highest 
proportion of failure was among defaulters (n=90), followed by transferred 
out (n=26) and deaths (n=11). Nationality and education had moderate 
positive association with treatment success, while males, rural residents and 
smokers had week negative association. Nationality, gender, area of 
residence, diabetes and smoking were significantly associated with treatment 
default while diabetes had moderate negative association. In general, 
knowledge about TB within the healthy and diseased population was in 
adequate. The study identified number of gaps in the area of transmission, 
risk factors, diagnosis and prevention of tuberculosis. Furthermore, these 
gaps predominated in non Libyans respondents, rural residents and those 
with lower education and monthly income. For smear positive pulmonary 
tuberculosis patients, the 85% WHO/IUATLD target for successful outcome 
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has not been achieved. Improving clinical and laboratory infrastructure in 
peripheral areas, educating defaulters about benefits of completing therapy 
and stratifying foreigners as high risk groups could improve treatment 
success rate. Furthermore, specialized educations programs should be 
developed to disseminate tuberculosis knowledge to patients and community 
members, especially for those falling in marginalized strata.    
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 CHAPTER ONE 
INTRODUCTION 
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1.1 Introduction 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium 
tuberculosis. It is estimated that one third of world’s population is affected with this 
disease and it causes two million deaths every year (Kherad et al., 2009, World Health 
Organization, 2006a). Since the mid 80’s with the advent of HIV/AIDS, the prevalence 
of TB has been increasing especially in Sub-Saharan Africa (Okot-Nwang et al., 1993). 
The incidence of TB among HIV infected patients is 45% and about 50% of HIV 
infected patients will develop TB in their lifetime (Okot-Nwang et al., 1993). It has 
been documented that TB situation has worsened over the past two decades in Africa 
owing to the HIV/AIDS epidemic (Borgdorff et al., 2002). The African region has the 
highest estimated incidence rate of 356 per 100,000 populations per year (World Health 
Organization, 2006b). Eighty percent of all cases worldwide occur in Sub-Saharan 
Africa and South East Asia (Dye et al., 1999). In 2005, it was reported, that there were 
about 24 new TB cases in Libya (all forms) (per 100,000 populations) (World Health 
Organization, 2006c). In 2007, incidence rate of TB in Libya was 17 cases (all forms) 
per 100,000 populations (TB Unit of the WHO Regional Office for Eastern-
Mediterranean Region, 2007). However in 2008, incidence rate of TB increased up to 
40 cases (all forms) per 100,000 populations (TB Unit of the WHO Regional Office for 
Eastern-Mediterranean Region., 2008). This increase in incidence rate is possibly a 
result influx of immigrants from Saharan and Sub-Saharan Africa (World Health 
Organization, 2007b), where incidence rate for TB is more than 300 cases (all forms) 
per 100,000 populations (World Health Organization, 2006c). The task of TB 
management is quite difficult for patients and providers because of its longer duration 
3 
 
(Bass Jr et al., 1994). In order to combat treatment challenges, worldwide, Directly 
Observed Treatment Short Course Strategy (DOTS) was adopted in mid 1990s which 
formed the basis of TB control (World Health Organization, 2009). National 
Tuberculosis Program (NTP) of Libya adopted DOTS program in 1998 (World Health 
Organization, 2007b). Benghazi, Tripoli and Sebha are capital cities of Eastern, Western 
and Southern regions of Libya, respectively and each of these cities has a Regional 
Tuberculosis Control Center (RTC). Four TB hospitals are located in Benghazi, Shahat, 
Tripoli and Misurata. A total of 24 Peripheral Tuberculosis Control Centers (PTCC) are 
located in various peripheral areas of the country to assist patients in completion of their 
treatment (Elghoul MT, 1981). Global targets for TB control were set by World Health 
Assembly (WHA) in 1991 (Dye, 2006). According to these targets, case detection for 
new sputum smear positive TB must be at least 70% with a cure rate not less than 85% 
(World Health Organization, 1991). Achieving these goals requires the active 
participation of the community by creating awareness on the causes, symptoms, 
management, preventive measures, and information on the availability of services.  
1.2 Problem Statement 
World Health Organization provided evidence of a gradual increase in the 
prevalence of TB in Libya from 2000 to 2006. Moreover global target for TB control 
was not achieved (World Health Organization, 2006c, World Health Organization, 
2007c). African region has the highest rate per capita of TB incidence in the World, 
and most of the worst affected countries are located in Sub-Saharan Africa (Kim, 
2002). As a matter of fact, Libya is nearest to Sub-Sahara countries and thus having 
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greater chances of TB outbreak (World Health Organization, 2007c). Higher 
incidence of TB might be consequence of increase in legal or illegal immigration 
from Africa across southern border from Sub-Saharan Africa or lack of appropriate 
knowledge of TB in public (World Health Organization, 2007c). Existing literature 
do not provide any information on the factors that significantly affect successful TB 
treatment outcomes. Furthermore, no data is available to provide an insight of 
patient’s and general public knowledge about TB in Libya (World Health 
Organization, 2011). Therefore, the aim of the present study is to evaluate the factors 
significantly affecting TB treatment outcomes as well as to assess the TB knowledge 
in general public and TB patients. Findings of this study will enable DOTS providers 
and policymakers to devise appropriate interventions to shape NTP of Libya 
according to current requirements. 
1.3 Rational of the Study  
Libya, like many other countries, uses the Tuberculosis Control Programme 
(TCP) for proper patient registration and reporting (World Health Organization, 2007b) 
World Health Organization has reported that no studies have been conducted in Libya 
focusing on knowledge of TB among general public and TB patients (World Health 
Organization, 2006a, World Health Organization, 2011). Knowledge about any disease 
is fundamental to optimize patients treatment and to improve their quality of life 
(Jaramillo, 2001).  Therefore, findings of this study will serve as a baseline data about 
knowledge of TB among general public and TB patients in Libya. This will allow health 
care professionals and DOTS providers to shape a comprehensive awareness program 
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for awareness of TB. Secondly, to-date no study has explored TB treatment outcomes 
according to World Health Organization Guidelines. Likewise, no data is available on 
factors that significantly affect treatment outcomes. Therefore, current study will 
provide an insight of factors that significantly affect treatment outcomes.  
1.4 Conceptual Framework  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Conceptual Framework of the Study 
Prevalence of TB in Libya from 2000 to 2006 
Evaluation of 
tuberculosis 
treatment outcomes 
Assessment of knowledge 
about TB among general 
and diseased population 
Factor associated with poor knowledge and treatment outcomes 
Planning for health educational 
strategies to improve patients’ 
knowledge for disease state 
management.  Provide information 
for policy makers in improving 
current patient’s management 
activities.  
Assistance 
in lowering 
current TB 
prevalence 
in Libya 
Result
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1.5 Significance of the Study 
Most difficult task of TB treatment is to convince patients to take their medications 
regularly without any interruption (Munro et al., 2007). For successful treatment 
outcomes, patient co-operation is essential (Sumartojo, 1993). Lack of patient 
motivation can be associated with in adequate knowledge about TB (Demissie et al., 
2002). Poor knowledge may lead to treatment failure, relapse and default from treatment 
(Dodor and Afenyadu, 2005). Moreover, these adverse consequences not only 
significantly affect patients but also their families and society. This study is the first of 
its kind in North East Libya for assessment of TB knowledge among general public and 
TB patients. Moreover, the success of DOTS depends on timely case detection and early 
medical management. To date, Libya has not achieved 85% treatment success rate set 
by WHO (World Health Organization, 2011). Therefore, results of this study would 
provide a baseline data to the decision makers for appropriate management of TB in 
Libya. Some of the possible policy implications can be: 
 Proportion of cases with successful outcome could be improved by provision of 
modern health care facilities at peripheral areas. 
 There is strong need for awareness among health care professionals and 
immigration authorities to ensure treatment completion of foreigners.  
 Adequate professional commitment and expertise of health care professionals 
can result in improvement of treatment success rates.   
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1.6 Study Objectives  
The objectives of this study are: 
1) To assess the level of knowledge of the Libyan population concerning 
etiology, mode of transmission, diagnosis, risk factors, treatment and 
prevention of TB. 
2) To assess the knowledge of TB patients concerning etiology, mode of 
transmission, diagnosis, risk factors, treatment and prevention of TB. 
3) To evaluate treatment outcomes of newly diagnosed pulmonary tuberculosis 
patients (PTB) in two TB hospitals of North East Libya.  
1.7 Thesis Overview 
This thesis is composed of 6 chapters, including the present chapter. Each 
chapter’s brief overview is outlined below 
1.7.1 Chapter One 
This chapter provides a general overview of the research problem. It also 
presents the general flow of the whole research project. 
1.7.2 Chapter Two 
Chapter two frames the literature review for the thesis. The chapter reflects both 
the diversity of issues that are addressed at global level concerning the management and 
social aspects of TB. This chapter also highlights the need to concentrate on the 
neglected aspects of TB in Libya.  
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1.7.3  Chapter Three 
This chapter describes the methodology and findings from quantitative survey 
designed to assess knowledge of TB in general public in northern states of Libya. This 
chapter is divided into two parts. Part I mainly describes study design and the steps 
adopted to develop a valid questionnaire for assessment of TB knowledge and second 
part presents findings and discussion. 
1.7.4 Chapter Four 
This chapter describes the methodology and findings from quantitative survey 
designed to evaluate knowledge of tuberculosis among newly diagnosed TB patients in 
two TB hospitals in North East Libya. This chapter also provides an overview of 
methodological approaches adopted to attain this specific objective.  
1.7.5 Chapter Five  
This chapter describes treatment outcomes of TB in two hospitals of North East 
Libya during 2007 and 2008. This chapter also describes the factors which are 
significantly associated with successful treatment outcomes. This chapter also highlights 
the factors significantly associated with treatment default.   
1.7.6 Chapter Six 
Chapter six draws the thesis to conclusion and suggested recommendations for 
further research. 
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 CHAPTER TWO  
LITERATURE REVIEW 
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2.1  Global Epidemiology of Tuberculosis 
Tuberculosis is an airborne disease caused by the Mycobacterium tuberculosis 
and is still one of the most deadly, and disabling diseases in the developing world 
(Beltz, 2011, Borgdorff et al., 2002, Dye et al., 2005). The WHO estimates that 
approximately one-third of the global community is infected with Mycobacterium 
tuberculosis (Dye et al., 2005). Worldwide, in 1995 there were about 9 million new 
cases of TB with 3 million deaths every year (Ernesto Montoro and Rodolfo Rodriguez, 
2007). In 2007, annual incidence rate of TB raised up to 9.27 million new cases from 
9.24 million in 2006 (Glaziou et al., 2009). Asia (55%) and Africa (31%) shared the 
maximum burden, with small proportions of cases in the Eastern Mediterranean Region 
(6%), the European Region (5%) and the Region of the Americas (3%) (Glaziou et al., 
2009). Current trends suggest that TB will be among the ten leading causes of global 
disease burden in the year 2020 (Murray and Lopez, 1997).  The five countries that rank 
first to fifth in terms of total numbers of cases in 2007 are India (2.0 million), China (1.3 
million), Indonesia (0.53 million), Nigeria (0.46 million) and South Africa (0.46 
million). African region has the highest estimated incidences rate (356/100,000 
populations) (Dye, 2006, World Health Organization, 2006c). The World Health 
Organization has reported that incidence rate in Sub-Saharan Africa is nearly twice as 
that of the South-East Asia (World Health Organization, 2011). 
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2.2 Epidemiology of Tuberculosis in Libya 
TB was documented as prevalent in 1887 in the coastal district western region of 
Libya, but it was found hardly to exist in the countryside (Elghoul MT, 1981). In 1912, 
88 cases were reported in the city of Tripoli, and few cases in other parts of the western 
region. An investigation in 1930 in 72 different places in southern region revealed only 
two cases (Elghoul MT, 1981). The incidence of TB in Libya increased with the 
industrial revolution in 1960. Due to this revolution, people especially from southern 
region moved into cities, particularly in capital city, Tripoli. As a disease prevention 
strategy in 1953, Bacille Calmette-Guérin (BCG) vaccination campaign was conducted 
throughout the country (Elghoul MT, 1981). In 2007, incidence rate of TB in Libya was 
17 cases (all forms) per 100,000 populations (World Health Organization, 2007b). 
However in 2008, incidence rate of TB increased up to 40 cases (all forms) per 100,000 
populations (World Health Organization, 2007d). This increase in incidence rate is 
possibly a result of increasing immigrants from Saharan and Sub- Saharan Africa, 
where incidence rate for TB is more than 300 cases (all forms) per 100, 000 population 
(World Health Organization, 2008b).  Incidence of Multi-drug resistant TB is 2.6% 
among the new cases and 39% among re-treatment cases (World Health Organization, 
2006d). Table 2.1 shows the case detection of new smear positive cases during 1971 to 
2008 (National Center for Disease Control Libya, 2008). 
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Table 2.1: Case detection of new smear positive pulmonary TB patient’s from 
1971 to 2008 
Years Libyans  
n(%) 
Non Libyans    
n(%) 
Total 
1971 700 (90.4) 74 (9.6) 774 
1972 920 (91.6) 84 (8.4) 1004 
1973 964 (84.6) 176 (15.3) 1140 
1974 840 (71.2) 341 (28.9) 1181 
1975 715 (61.2) 423 (37.2) 1138 
1976 657 (65.4) 347 (34.6) 1004 
1977 739 (67.7) 352 (32.3) 1091 
1978 507 (63.7) 289 (36.3) 796 
1979 475 (64.8) 258 (35.2) 733 
1980 446 (63.5) 256 (36.5) 702 
1981 490 (57.4) 363 (42.6) 853 
1982 427 (55.2) 346 (44.8) 773 
1983 367 (55.3) 297 (44.7) 664 
1984 318 (59.7) 215 (40.3) 533 
1985 345 (69.1) 154 (30.9) 499 
1986 320 (69.4) 141 (30.6) 461 
1987 331 (68.1) 155 (31.9) 486 
1988 273 (62.3) 165 (37.7) 438 
1989 252 (54.3) 212 (45.7) 464 
1990 258 (53.9) 221 (46.1) 479 
1991 262 (49.8) 264 (50.2) 526 
1992 251 (45.9) 296 (54.1) 547 
1993 274 (45.7) 325 (54.3) 599 
1994 290 (48.7) 305 (51.3 ) 595 
1995 345 (55.1) 281 (44.9) 626 
1996 330 (64.1) 185 (35.9) 515 
1997 394 (62.8) 233 (37.2) 627 
1998 463 (62.9) 273 (37.1) 736 
1999 457 (56.9) 346 (43.1) 803 
2000 439 (63.7) 250 (36.3) 689 
2001 436 (64.5) 240 (35.5) 676 
2002 436 (62.8) 258 (37.2) 694 
2003 509 (66.6) 255 (33.4) 764 
2004 573 (65.7) 299 (34.3) 872 
2005 615 (71.5) 245 (28.5) 860 
2006          544 (73.02) 201 (26.98) 745 
2007 601 (77.8) 171 (22.2) 772 
2008 621 (71.3) 250 (28.7) 871 
Source: (National Center for Disease Control Libya, 2008)  
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2.3 Pathogenesis of Tuberculosis 
Primary site of tuberculosis infection is pulmonary alveoli, where 
Mycobacterium tuberculosis invades and replicates within the endosomes of alveolar 
macrophages (Kumar et al., 1992, Houben et al., 2006). The primary site of infection in 
the lungs is called the Ghon focus, and is generally located in either the upper part of the 
lower lobe, or the lower part of the upper lobe (Kumar et al., 1992). Bacteria are picked 
up by dendritic cells, which do not allow replication, although these cells can transport 
the bacilli to local (mediastinal) lymph nodes. TB can spread to other tissues and organs 
through the bloodstream where secondary TB lesions can develop in other parts of the 
lung (particularly the apex of the upper lobes), peripheral lymph nodes, kidneys, brain, 
and bone (Kumar et al., 1992, Herrmann and Lagrange, 2005). Each and every part of 
the body can be affected by TB though it rarely affects the heart, skeletal muscles, 
pancreas and thyroid (Agarwal et al., 2005). 
TB is an inflammatory condition with formation of granuloma. Macrophages, T-
lymphocytes, B-lymphocytes and fibroblasts aggregate to form a granuloma. 
Lymphocytes surround the infected macrophages. Cytokines such as interferon gamma, 
are secreted by T-lymphocytes which activates macrophages to destroy the bacteria with 
which they are infected (Kaufmann, 2002).  Cytotoxic T cells can also directly kill 
infected cells, by secreting perforin and granulysin (Houben et al., 2006).   When lung 
tissues are damaged bacteria get access to blood stream and spread through the body 
and set up many foci of infection. There they appear as tiny white tubercles in the 
tissues. This severe form of TB disease is most common in infants and the elderly and is 
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called miliary tuberculosis and has a fatality rate of approximately 20%, even with 
intensive treatment (Kim et al., 2003). In pulmonary tissue, destruction and necrosis are 
balanced by healing and fibrosis (Grosset, 2003). Affected tissue is replaced by scarring 
and cavities filled with cheese-like white necrotic material. During active disease, some 
of these cavities are joined to the air passages bronchi. When a person coughs with such 
condition he/she disperse droplets in air along with number of live bacteria (Cole and 
Cook, 1998). 
2.4 Transmission of Tuberculosis 
Patient of pulmonary tuberculosis (PTB) expel infectious aerosol droplets 
ranging from 0.5 to 5 µm in diameter. A single sneeze of infected patient can release up 
to 40,000 droplets (Cole and Cook, 1998). Each one of these droplets may have the 
capability of transmitting the disease. However, transmission is limited to patients with 
active PTB (Robbins et al., 2010). Since the infectious dose of Mycobacterium 
tuberculosis is very low, therefore, inhaling less than ten bacteria may cause an 
infection in healthy volunteer (Nicas et al., 2005, Behr et al., 1999). The probability of 
transmission from one person to another depends upon the number of infectious droplets 
expelled by a carrier; the effectiveness of ventilation, the duration of exposure, and the 
virulence of the Mycobacterium tuberculosis strain, people with prolonged, frequent, or 
intense contact with infected individuals are particularly at high risk.  It was observed 
that a single person with active TB have the threatening ability to infect 10–15 people 
per year (World Health Organization, 2011). TB can also be transmitted by eating meat 
infected with Mycobacterium bovis (Majoor et al., 2011). Some of the higher risk 
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groups are; smokers,  intravenous drug abusers , alcoholics, diabetics,  residents and 
employees of high-risk congregation settings, people with poor socioeconomic 
characteristics, malnourished, patients taking corticosteroids and patients who are 
immune-compromised (Behr et al., 1999). 
2.5 Diagnosis of Tuberculosis 
A complete medical evaluation for TB must include a medical history, a 
physical examination, a chest X-ray, microbiological smears, and cultures. Smear test 
alone or smear and culture tests are helpful in early detection of TB (Arenas et al., 2008, 
Zamarioli et al., 2009). New TB tests are being developed that offer the hope of cheap, 
fast and more accurate TB testing. These include polymerase chain reaction 
(Balasingham et al., 2009), detection of bacterial Deoxyribonucleic acid (DNA), assays 
to detect the release of interferon gamma in response to mycobacterium proteins such as 
ESAT-6 (Nahid et al., 2006) and Enzyme Linked Immunosorbent Assay (ELISA) 
(Chou et al., 2009). 
2.5.1 Medical History  
The medical history includes obtaining the symptoms of pulmonary TB such 
as history of cough for three or more weeks, chest pain, and hemoptysis. Systemic 
symptoms include low grade remittent fever, chills, night sweats, appetite loss, 
weight loss, easy fatigability (Cole and Cook, 1998). Medical history also includes 
prior TB exposure, infection or past history of TB treatment or any other high risk 
behavior like smokers, alcoholic, malnourished or immune-compromised patients. 
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TB should be suspected when a persistent respiratory illness in an otherwise healthy 
individual does not respond to regular antibiotics (Cole and Cook, 1998).  
2.5.2 Radiography 
Radiographic procedures for diagnosis of PTB are often based on abnormal 
chest radiographic findings in a patient with respiratory symptoms. Although the 
“classic” picture is that of upper lobe disease with infiltrates and cavity virtually, but 
patients can never be diagnosed of TB. However, chest radiographs may be used to 
rule out the possibility of PTB in a person who has a positive reaction to the 
tuberculin skin test and has no symptoms of disease (Robbins et al., 2010). In 
addition, a diographic pattern may be seen. In the era of AIDS, no radiographic 
pattern can be considered pathogenomonic (Mariani, 2000). Abnormalities on chest 
radiographs may be suggested.  
2.5.3 Microbiological studies  
A definitive diagnosis of TB can only be made by culturing Mycobacterium 
tuberculosis from a specimen taken from the patient’s sputum. Specimens may also 
include pus, Cerebrospinal fluid (CSF) or biopsied tissue (Robbins et al., 2010). 
However, a presumptive diagnosis is commonly based on finding of Acid-fast bacilli 
(AFB) on microscopic examination of a diagnostic specimen such as a smear of 
expectorated sputum or of tissue. For patients with suspected PTB, usually three 
sputum samples are collected early in the morning on different days (World Health 
Organization, 2009). In cases where there is no spontaneous sputum production, a 
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sample can be induced, usually by nebulizer inhalation of a saline (Brown et al., 
2007). 
2.5.4 Tuberculin Skin Test (TST) 
Tuberculin Skin Test (TST), Mantoux skin test is of limited value in the 
diagnosis of active TB because of its low sensitivity and specificity. False-negative 
reactions are common in immunosuppressed patients and in those with overwhelming 
TB. Positive reactions can be obtained when patients have been infected with 
Mycobacterium tuberculosis but do not have active disease or persons who have 
undergone Bacilli Calmette-Guerin (BCG) vaccination. In the absence of a history of 
BCG vaccination, a positive skin test may provide additional support for the 
diagnosis of TB in culture-negative cases (Huebner et al., 1993). 
2.5.5 Extra Pulmonary Tuberculosis (EPTB) 
TB of organs other than the lungs is called extra pulmonary tuberculosis. 
Mainly it includes the peripheral lymph nodes, abdomen, the pleura (TB pleurisy), 
skin, joints, bones, and the brain. The diagnosis of EPTB Tuberculosis is often 
difficult compared with PTB due to the low sensitivity of the diagnostic methods for 
the disease. Usually specimen samples from affected organs are taken for 
histopathological (HPE) examinations by pathologists (Sharma and Mohan, 2004). 
2.6  Treatment of Tuberculosis 
TB is a curable infectious disease but longer duration of its treatment is one of 
greatest barrier to treatment.  The aim of treatment is not only to cure the patients, but 
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also to prevent mortality, relapse and transmission of disease (World Health 
Organization, 2009).  
2.6.1 History of Tuberculosis Treatment 
Before discovering specific antibiotics for TB treatment, the mortality of 
patients with pulmonary disease was about 50%. By the end of 1980’s, TB was 98% 
curable.  The present TB chemotherapy is one of the most fabulous achievements in 
the field of medicine. The first trials of TB treatment began when Robert Koch 
(1882) discovered a staining technique that enabled him to see Mycobacterium 
tuberculosis. The discoveries of streptomycin in 1944, para-amino salicylic acid in 
1946, and isoniazid in 1952 led to the first effective cure for TB (Leung, 1999). 
2.6.2 Treatment of Latent Tuberculosis Infection (LTBI)  
Patients of LTBI are usually identified by TST. In order to prevent the 
development of active disease in the future, patients should be treated with isoniazid (10 
mg/kg/day or, at most, 300 mg/day) for six to nine months (Castelo Filho et al., 2004). 
Although, such treatment reduces the risk of active TB but it does not protect the patient 
from exogenous exposure. Candidates for treating latent TB infection are those included 
in high risk groups (Jasmer et al., 2002). 
2.6.3 Treatment of Active Tuberculosis Infection 
 Standard short course regimens are divided into an Initial intensive Phase (IP) 
or bactericidal phase and Continuation Phase (CP) or sterilization phase. Through the 
initial phase, the greater part of the tubercle bacilli are destroyed; symptoms are 
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resolved and generally the patient become noninfectious. The continuation phase is 
necessary to remove persisting Mycobacterium and avoid relapse (Yew, 2006). 
Isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin are listed as 
first line anti TB drugs. Table 2.2 shows available dosage forms and daily dose of each 
drug calculated on patient body weight. 
Table 2.2: Daily dose and available dosage forms of first line anti-tuberculosis 
drugs 
Drug Dosage 
form 
Available 
strengths
Daily dose Three times per 
week
Isoniazid Tablet 100 mg, 
300 mg 
5 mg/kg 
(max.300 mg) 
10 mg 
(max.900 mg) 
Rifampicin Tablet or 
capsule 
150 mg 
300 mg 
10 mg/kg 
(max.600 mg) 
10 mg 
(max.900 mg) 
Pyrazinamide Tablet 400 mg 15-30 mg/kg 35 mg 
Ethambutol Tablet 100 mg, 15-25 mg/kg 30 mg 
Streptomycin Powder for 
injection in 
vial 
400 mg 
1 g 
12-18 mg/kg 15 mg 
(max.1000 mg) 
Source: (World Health Organization, 2009)   
 
Like other drugs, anti TB drugs also produce adverse effects which are categorized as 
minor and major adverse drugs. Table 2.3 shows symptom base management of these 
adverse effects. 
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Table 2.3: Symptom based approach to managing side effects of anti TB drugs 
side-effects 
Symptom based approach to 
managing side effects of anti TB 
drugs Side-effects 
Drug(s)probably responsible Management 
Major Stop responsible drug(s) and refer to clinician urgently 
Skin rash with or without itching Streptomycin, isoniazid, rifampicin, 
pyrazinamide 
Stop anti-TB drugs 
Deafness (no wax on otoscopy) Streptomycin Stop streptomycin 
Dizziness (vertigo and nystagmus) Streptomycin Stop streptomycin 
Jaundice (other causes excluded), 
hepatitis 
Isoniazid, pyrazinamide, rifampicin Stop anti-TB drugs 
Confusion (suspect drug-induced 
acute liver failure if there is 
jaundice) 
Most anti-TB drugs Stop anti-TB drugs 
Visual impairment (other causes 
excluded) 
Ethambutol Stop ethambutol 
Shock, purpura, acute renal failure Rifampicin Stop rifampicin 
Decreased urine output Streptomycin Stop streptomycin 
Minor Continue anti-TB drugs, check drug doses 
Anorexia, nausea, abdominal pain Pyrazinamide, rifampicin, isoniazid Give drugs with small meals or just 
before bedtime, and advice patient to 
swallow pills slowly with small sips 
of water. If symptoms persist or 
worsen, or there is protracted 
vomiting or any sign of bleeding, 
consider the side-effect to be major 
and refer to clinician urgently. 
Joint pains Pyrazinamide Aspirin or non-steroidal anti-
inflammatory drug, or paracetamol 
Burning, numbness or tingling 
sensation in the hands or feet 
Isoniazid Pyridoxine 50–75 mg daily (3) 
Drowsiness Isoniazid Reassurance. Give drugs before 
bedtime 
Orange/red urine Rifampicin Reassurance. Patients should be told 
when starting treatment that this may 
happen and is normal 
Flu syndrome (fever, chills, 
malaise, headache, bone pain) 
Intermittent dosing of rifampicin Change from intermittent to daily 
rifampicin administration (3) 
Source: (World Health Organization, 2009) 
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2.6.4 Standardized Treatment Regimen  
Standardized treatment means that all patients in defined group receive the same 
treatment regimen (World Health Organization, 2009). Table 2.4 shows standardized 
treatment regimen for newly diagnosed TB patients. 
Table 2.4: Standard regimens for new TB patients 
Initial intensive phase of treatment Continuation phase of treatment 
2 months HRZEa 4 months HR 
2 months HRZE 4 months HREb 
2 months HRZE 4 months (HR)3c 
a WHO no longer recommends omission of ethambutol during the intensive phase of 
treatment for patients with non-cavitary, smear-negative PTB or EPTB who are known 
to be HIV-negative. In tuberculosis meningitis, ethambutol should be replaced by 
streptomycin. 
b In settings where the level of isoniazid resistance among new TB cases is high and 
isoniazid susceptibility testing is not done (or results are not available) before the 
continuation phase begins.  
c Three times weekly for four months provided that each dose is directly observed.  H = 
isoniazid, R= rifampicin, Z = pyrazinamide, E= ethambutol, S = streptomycin (World 
Health Organization, 2009). 
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2.6.5 Re-treatment of TB 
Previously treated TB patients include those patients treated as new cases for 
more than one month who are now smear or culture positive (failure, relapse, return 
after default). Re-treatment cases have a higher likelihood of drug resistance, which 
may have been acquired through inadequate prior chemotherapy. Standard treatment 
regimen for re-treatment case is as follows; 2HRZES/1HRZE/5HRE. This standardized 
regimen can cure patients excreting bacilli still fully sensitive to the drugs and those 
excreting bacilli resistant to isoniazid and / or streptomycin (World Health 
Organization, 2009).  
2.6.6 Treatment of Resistant TB 
Multi-drug resistant Tuberculosis (MDR-TB) is defined as TB that is resistant at 
least to isoniazid and rifampicin. In designing the country’s MDR-TB treatment 
component and integrating it into the national program, NTP managers are strongly 
encouraged to make full use of the Green Light Committee (GLC). The GLC is a 
subgroup of the MDR-TB Working Group of the Stop TB Partnership, and an advisory 
body of WHO that promotes access to (and monitors the use of) quality-assured, life-
saving MDR-TB treatment (World Health Organization, 2009).  
For MDR treatment, anti-TB drugs are grouped according to efficacy, 
experience of use and drug class (Table 2.5). All the first-line anti-TB drugs are in 
Group 1, except streptomycin, which is classified with the other, injectable agents in 
Group 2. All the drugs in Groups 2–5 (except streptomycin) are second-line, or reserve 
drugs (World Health Organization, 2008b). 
23 
 
 Table 2.5: Groups of drugs to treat MDR-TB 
Group Drugs (abbreviations) 
Group 1 
First-line oral agents 
Pyrazinamide (Z) 
Ethambutol (E) 
Rifabutin (Rfb) 
Group 2 
Injectable agents 
Kanamycin (Km) 
Amikacin (Am) 
Capreomycin (Cm) 
Streptomycin (S) 
Group 3 
Fluoroquinolones 
Levofloxacin (Lfx) 
Moxifloxacin (Mfx) 
Ofloxacin (Ofx) 
Group 4 
Oral bacteriostatic second-line agents 
Para-aminosalicylic acid (PAS) 
Cycloserine (Cs) 
Terizidone (Trd) 
Ethionamide (Eto) 
Protionamide (Pto) 
Group 5 
Agents with unclear role in treatment of drug 
resistant-TB 
Clofazimine (Cfz) 
Linezolid (Lzd) 
Amoxicillin/clavulanate (Amx/Clv) 
 Thioacetazone (Thz) 
Imipenem/cilastatin (Ipm/Cln) 
High-dose isoniazid (high-dose H)b 
Clarithromycin (Clr) 
 
High-dose isoniazid is defined as 16–20 mg/kg/day. Some experts recommend using 
high-dose isoniazid in the presence of resistance to low concentrations of isoniazid 
(>1% of bacilli resistant to 0.2 μg/ml but susceptible to 1 μg/ml of isoniazid), whereas 
isoniazid is not recommended for high-dose resistance (>1% of bacilli resistant to 1 
μg/ml of isoniazid) (World Health Organization, 2009) (World Health Organization, 
2008b). 
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2.7 Directly Observed Therapy Short Course (DOTS) 
1. Direct observed treatment short course (DOTS) can improve adherence to 
treatment as it requires the patients to swallow their medications under direct 
observation of DOTS providers. Around 10 million infectious patients have been 
successfully treated under the DOTS programmes since it was first introduced 
on a global scale in 1995.  
  Five fundamental principles of DOTS are as follows: 
i. Political commitment and resources 
ii. Accurate diagnosis by AFB smear-positive 
iii. Standardized short-course treatment for all patients with directly 
observed  
iv. Regular provide with good and adequate free drug, and finally  
v. Monitoring of the outcome of the patients (World Health 
Organization, 2009). 
2-     In 2004, 183 countries and territories implemented DOTS strategy and 83% of   
the world’s population lived in DOTS-covered countries in the end of 2004. A total 
of 21.5 million TB patients and 10.7 million AFB smear-positive patients were 
treated in DOTS programs over 10 years ranging from 1995-2004 (Ernesto 
Montoro and Rodolfo Rodriguez, 2007). Throughout the world, case detection rate 
by DOTS increased from 11% in 1995 to approximately 45% by 2003, and 
